Insights for Investors
Neoleukin Therapeutics, Inc. (NLTX) stock surged +1.45%, trading at $3.49 on NASDAQ, up from the previous close of $3.44. The stock opened at $3.45, fluctuating between $3.42 and $3.59 in the recent session.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Employees | 7 |
Beta | 1.102 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) stock price is $3.49 in the last trading session. During the trading session, NLTX stock reached the peak price of $3.59 while $3.42 was the lowest point it dropped to. The percentage change in NLTX stock occurred in the recent session was 1.45% while the dollar amount for the price change in NLTX stock was $0.05.
The NASDAQ listed NLTX is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Neoleukin Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. David Baker
Co-founder & Member of Scientific Advisory Board
Dr. David Baker M.D., Ph.D.
Co-founder & Member of Scientific Advisory Board
Dr. Bill Arthur
Vice President & Head of Research
Mr. Umut Ulge
Vice President of Clinical Devel.
Dr. Priti Patel M.D., M.S.
Chief Medical Officer
Dr. Carl Walkey Ph.D.
Senior Vice President of Corporation Devel.
Mr. Kamran Alam
Senior Strategic Advisor
Ms. Donna M. Cochener-Metcalfe J.D.
Gen. Counsel & Interim Chief Executive Officer
Dr. Jonathan G. Drachman M.D.
Chief Executive Officer, Pres, Principal Financial Officer & Director
Mr. Sean Michael Smith
Interim Chief Financial Officer
NLTX's closing price is 2.05% higher than its 52-week low of $3.42 where as its distance from 52-week high of $18.80 is -81.44%.
Number of NLTX employees currently stands at 7.
Official Website of NLTX is: https://www.neoleukin.com
NLTX could be contacted at phone 855 226 6447 and can also be accessed through its website. NLTX operates from 188 East Blaine Street, Seattle, WA 98102, United States.
NLTX stock volume for the day was 109.1K shares. The average number of NLTX shares traded daily for last 3 months was 5.52K.
The market value of NLTX currently stands at $8.20M with its latest stock price at $3.49 and 2.35M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com